155 related articles for article (PubMed ID: 28210141)
1. Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer.
Stasi I; Cappuzzo F
Lung Cancer (Auckl); 2014; 5():43-50. PubMed ID: 28210141
[TBL] [Abstract][Full Text] [Related]
2. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.
DeRose P; Thorpe PE; Gerber DE
Immunotherapy; 2011 Aug; 3(8):933-44. PubMed ID: 21843081
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.
Chalasani P; Marron M; Roe D; Clarke K; Iannone M; Livingston RB; Shan JS; Stopeck AT
Cancer Med; 2015 Jul; 4(7):1051-9. PubMed ID: 25826750
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gerber DE; Spigel DR; Giorgadze D; Shtivelband M; Ponomarova OV; Shan JS; Menander KB; Belani CP
Clin Lung Cancer; 2016 May; 17(3):169-76. PubMed ID: 27265742
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Grilley-Olson JE; Weiss J; Ivanova A; Villaruz LC; Moore DT; Stinchcombe TE; Lee C; Shan JS; Socinski MA
Clin Lung Cancer; 2018 Jul; 19(4):e481-e487. PubMed ID: 29631965
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
Gerber DE; Hao G; Watkins L; Stafford JH; Anderson J; Holbein B; Öz OK; Mathews D; Thorpe PE; Hassan G; Kumar A; Brekken RA; Sun X
Am J Nucl Med Mol Imaging; 2015; 5(5):493-503. PubMed ID: 26550540
[TBL] [Abstract][Full Text] [Related]
7. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Gerber DE; Stopeck AT; Wong L; Rosen LS; Thorpe PE; Shan JS; Ibrahim NK
Clin Cancer Res; 2011 Nov; 17(21):6888-96. PubMed ID: 21989064
[TBL] [Abstract][Full Text] [Related]
8. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.
Cheng X; Li L; Thorpe PE; Yopp AC; Brekken RA; Huang X
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):583-591. PubMed ID: 26847681
[TBL] [Abstract][Full Text] [Related]
10. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial.
Mokdad AA; Zhu H; Beg MS; Arriaga Y; Dowell JE; Singal AG; Yopp AC
Target Oncol; 2019 Oct; 14(5):541-550. PubMed ID: 31429027
[TBL] [Abstract][Full Text] [Related]
12. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids.
He J; Luster TA; Thorpe PE
Clin Cancer Res; 2007 Sep; 13(17):5211-8. PubMed ID: 17785577
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma.
Meyer J; Arriaga Y; Anandam J; Karri S; Syed S; Verma U; Abdelnaby A; Raja G; Dong Y; Beg MS; Balch G
Am J Clin Oncol; 2018 Oct; 41(10):972-976. PubMed ID: 28763330
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
16. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma.
He J; Yin Y; Luster TA; Watkins L; Thorpe PE
Clin Cancer Res; 2009 Nov; 15(22):6871-80. PubMed ID: 19887482
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Zhang YF; Yu YF; Lu S
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
